000062055 001__ 62055
000062055 005__ 20190819101354.0
000062055 0247_ $$2doi$$a10.4321/S1130-01082013000100005
000062055 0248_ $$2sideral$$a100050
000062055 037__ $$aART-2013-100050
000062055 041__ $$aeng
000062055 100__ $$aOrtiz-Lucas, M.
000062055 245__ $$aEffect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis
000062055 260__ $$c2013
000062055 5060_ $$aAccess copy available to the general public$$fUnrestricted
000062055 5203_ $$aBackground and objectives: immune system alteration in irritable bowel syndrome (IBS) patients may be modulated by probiotics. We assessed the efficacy of some probiotic species in alleviating characteristic IBS symptoms. Material and methods: a meta-analysis of all identified randomized controlled trials comparing probiotics with placebo in treating IBS symptoms was performed with continuous data summarized using standardized mean differences (SMDs) with 95% confidence intervals (95% CIs), where appropriate. The randomeffects model was employed in cases of heterogeneity; otherwise, fixed-effects models were used. Results: meta-analysis was performed with 10 of 24 studies identified as suitable for inclusion. Probiotics improved pain scores if they contained Bifidobacterium breve (SMD, -0.34; 95% CI, -0.66; -0.02), Bifidobacterium longum (SMD, -0.48; 95% CI, -0.91; -0.06), or Lactobacillus acidophilus (SMD, -0.31; 95% CI, -0.61; -0.01) species. Distension scores were improved by probiotics containing B. breve (SMD, -0.45; 95% CI, -0.77; -0.13), Bifidobacterium infantis, Lactobacillus casei, or Lactobacillus plantarum(SMD, -0.53; 95% CI, -1.00; -0.06) species. All probiotic species tested improved flatulence: B. breve (SMD, -0.42; 95% CI, -0.75; -0.10), B. infantis, L. casei, L. plantarum(SMD, -0.60; 95% CI, -1.07; -0.13), B. longum, L. acidophilus, Lactobacillus bulgaricus, and Streptococcus salivarius ssp. thermophilus (SMD, -0.61; 95% CI, -1.01; -0.21). There was not a clear positive effect of probiotics concerning the quality of life. Conclusions: some probiotics are an effective therapeutic option for IBS patients, and the effects on each IBS symptom are likely species-specific. Future studies must focus on the role of probiotics in modulating intestinal microbiota and the immune system while considering individual patient symptom profiles.
000062055 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000062055 590__ $$a1.317$$b2013
000062055 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b64 / 75 = 0.853$$c2013$$dQ4$$eT3
000062055 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000062055 700__ $$aTobias, A.
000062055 700__ $$0(orcid)0000-0002-7997-3619$$aSaz, P.$$uUniversidad de Zaragoza
000062055 700__ $$0(orcid)0000-0003-1272-7365$$aSebastián, J.J.$$uUniversidad de Zaragoza
000062055 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000062055 773__ $$g105, 1 (2013), 19-36$$pRev. esp. enferm. dig.$$tRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva$$x1130-0108
000062055 8564_ $$s266013$$uhttps://zaguan.unizar.es/record/62055/files/texto_completo.pdf$$yVersión publicada
000062055 8564_ $$s8583$$uhttps://zaguan.unizar.es/record/62055/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000062055 909CO $$ooai:zaguan.unizar.es:62055$$particulos$$pdriver
000062055 951__ $$a2019-08-19-09:51:58
000062055 980__ $$aARTICLE